Skip to main content
Premium Trial:

Request an Annual Quote

NIH Seeks Industry Partners for RNAi Research Initiative

NEW YORK (GenomeWeb News) - The National Institutes of Health is looking for businesses with RNAi-related know-how and technology to help support a planned trans-NIH effort to spread the use of RNAi within its institutes.
 
NIH said in a notice on Friday that it intends to meet with industry representatives in December for their comments and for information, and plans to discuss entering pricing arrangements with prospective contracts to support these RNAi-centered efforts.
 
NIH said in a request for information that its RNAi initiative aims to facilitate moderate-throughput and high-throughput screens “that ultimately target entire genomes,” and will focus on human and mouse models.
 
NIH intends to develop a list of firms and suppliers that may provide reagents and high-throughput screens, negotiate pricing, develop ordering procedures, and provide technical support to the researchers.
 
The moderate-throughput projects will aim for “uniform pricing and a mechanism for technical support.”
 
“Purchase units for both transfection and stable integration of human and mouse cells should be sufficient for triplicate experiments for each target gene, siRNAs, shRNAs, and other potential novel reagents … of interest.” The agency added that pricing for individual target genes, plates, and transfection reagents is planned.
 
On the high-throughput end, NIH said it seeks reagent pricing information and that pilot projects may require “close contact” between NIH researchers and the businesses involved in the initiative.
 
More information about the meeting and the RFI can be found here.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.